Standard & Poor's
http://www2.standardandpoors.comStandard & Poor’s, a division of McGraw-Hill (NYSE: MHP), produces financial research and analysis on stocks and bonds. It provides credit ratings on public and private corporations and is designated as a Nationally Recognized Statistical Rating Organization (NRSRO) by the SEC. The firm’s long-term credit ratings range from “AAA” to “D” and its short-term credit ratings range from “A-1” to “D”. Standard & Poor’s also publishes indexes including the S&P 500.
View Older Stories
-
6 healthcare stocks Argus considers 'gems'
-
Argus sees 'some possible gems right now in the Healthcare sector'
-
Eli Lilly, UPS ahead, SoftBank's surprise loss - what's moving markets
-
Dow Jones, Nasdaq, S&P 500 weekly preview: Better than feared Q2 results, worse than expected reactions
-
Amgen & Eli Lilly upgraded to Overweight at Wells Fargo, Merck downgraded to Equal Weight
-
Q2 Earnings Season Should Be a Negative Catalyst for Equities - Morgan Stanley
-
Eli Lilly & Co. (LLY) Outlook Revised to Stable From Negative at S&P
-
Eli Lilly (LLY) Shares Trade Lower Despite Earnings, Guidance Beat; Analyst 'Encouraged by Fundamentals and Pipeline'
-
Pre-Open Stock Movers 03/15: (GNMK) (ZKIN) (NXPI) Higher; (LLY) (DKNG) (MGNI) Lower (more...)
-
Biotech ETF (IBB) Lower After Biogen (BIIB) FDA Panel Negative Vote on Question 1
-
S&P 500, Dow finish lower in volatile trade on dour Fed forecasts
-
UBS Downgrades Eli Lilly (LLY) to Neutral on Valuation
-
UPDATE: Goldman Sachs Upgrades Eli Lilly (LLY) to Conviction Buy
-
S&P reaches highest level since February as Alphabet shares soar
-
Earnings, bank shares propel S&P 500 to record high
-
Pharma, Biotech Stocks Surge as Trump's Draft Order on Drug Prices Seen as Favorable (IBB) (XBI)
-
Goldman Sachs Removes Eli Lilly (LLY) from Conviction Buy List
-
Dow, S&P 500 set record high closes ahead of holiday
-
Dow, S&P close at records; U.S. yields, dollar at multi-year highs
-
Market Wrap: U.S. Auto Sales Have Banner Year; Twitter Said Mulling Key Character-Limit Initiative
-
Market Wrap: Revised Q3 GDP Shows Growth; E. Coli Breakout Reported at Costco; KaloBios Volatility Continues
-
Market Wrap: Existing Sales Ramp in Sept.; Abbvie Hit on FDA Warning for HCV Drug; Amazon's Q3 Results Stun Street
-
Market Wrap: Dell Makes it Official with EMC; Lilly Hit on Drug Halt; Ferrari IPO Revs up
-
Credit Suisse Upgrades Eli Lilly (LLY) to Outperform
-
U.S. stock futures higher after two-day selloff
-
Deutsche Bank Downgrades Eli Lilly (LLY) to Hold
-
Market Wrap: Fed Doesn't See Rate Hike in Q1; Employment Shows Robust Expansion in Dec.; FHA Gets Rate Cut
-
Market Wrap: CEO Retirement Party; SAP's Big Purchase; Home Depot Outlines Card Breach, Outlook
-
Market Wrap: Housing Sales Miss in June; Earnings Abound; SodaStream 'Pops' on Speculation
-
Market Wrap: Health Care Mergers Aplenty; Conn's Pops on Greenlight Stake; GM (GM) Conducts Major Engineering Overhaul
-
Market Wrap: GM Energizes Battery Initiative; Nokia, Microsoft Deal Approved; Tesla's Business Side
-
Market Wrap: Initial Claims Show Surprise Gain; Tesla's Cross-Country Trip
-
Market Wrap: Yellen Up Next; Apple's Record App Store Sales; Micron Trumps Views
-
Market Wrap: Icahn is Now 'iCahn' with Latest Move; Ackman, JCPenney Part; Airline Merger Hits Big Bump
-
Jefferies Lifts PT on Pharmaceuticals Stocks (ABBV) (NVS) (SNY) (PFE)
-
Market Wrap: (Most) Banks Pass Fed Muster; JPMorgan in Senate Hot Seat; Kerkorian Likes MGM
-
Market Wrap: Q3 Earnings on the Brink; UnitedHealth Goes Big in LatAm; Lilly Inches Close to Alzheimer's Treatment
-
Market Wrap: US Manufacturing Hits the Skids; Apple Settles 'iPad' Suit; Merger Monday!
-
George Soros' Hedge Fund Slashes Stake In Gold ETF (GLD), Raises Stake in Citi (C) and AT&T (T)
-
Apple (AAPL), Halliburton (HAL), Google (GOOG) Among Most Popular Stocks for 2011
-
Meet Your New Dividend Aristocrats (MKC, HRL, ECL)
-
S&P Cuts Rating on Eli Lilly (LLY) from AA to AA-; Outlook Stable
-
Citi on U.S. Major Pharmaceuticals: 2Q10 Outperformance Expected
-
Citi Issues Q1 Preview on U.S. Major Pharmaceuticals; Merck (MRK) Remains 'Top Pick'
-
ARGUS Downgrades Eli Lilly (LLY) to Hold
-
Citi Maintains 'Hold' Rating on Eli Lilly (LLY), Lowers Price Target
-
Top 10 News Items 8/25-8/29: Oil/Nat Gas See Volatile Trading on Gustav Concerns; Fannie/Freddie Nearly Double; FDIC Banking Profile Shows Worst Quarter Since '91